Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison
暂无分享,去创建一个
N. Koulouris | N. Rovina | A. Koutsoukou | E. Andreakos | A. Mentis | S. Tsiodras | E. Koukaki | M. Manioudaki | I. Galani | P. Fragkou | O. Koltsida | V. Rapti | V. Panou | Ioanna E. Galani | Vicky Lampropoulou | Vasiliki Triantafyllia | Eleftherios Pavlos | Vasiliki Panou
[1] Zhihua Zheng,et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.
[2] Nicolas Carlier,et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.
[3] C. Hunter,et al. Cytokine Storms: Understanding COVID-19 , 2020, Immunity.
[4] Zhenyu Li,et al. The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.
[5] M. Llorian,et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection , 2020, Science.
[6] F. Granucci,et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition , 2020, Science.
[7] Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) , 2020, Chinese medical journal.
[8] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[9] T. Liang,et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.
[10] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[11] Malik Peiris,et al. Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.
[12] Eric H. Y. Lau,et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.
[13] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[14] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[15] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[16] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[17] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[18] Qin Ning,et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .
[19] R. Baric,et al. Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection , 2019, mBio.
[20] E. Andreakos,et al. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control , 2018, Current Opinion in Immunology.
[21] Bernstein,et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza a , 2018 .
[22] S. Kotenko,et al. Interferon‐&lgr; Mediates Non‐redundant Front‐Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness , 2017, Immunity.
[23] K. Fitzgerald,et al. Inflammasome Complexes: Emerging Mechanisms and Effector Functions , 2016, Cell.
[24] David K. Meyerholz,et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.
[25] E. Andreakos,et al. Neutrophils in viral infections: Current concepts and caveats , 2015, Journal of leukocyte biology.
[26] A. Sher,et al. Type I interferons in infectious disease , 2015, Nature Reviews Immunology.
[27] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[28] Sophia Davidson,et al. Pathogenic potential of interferon αβ in acute influenza infection , 2014, Nature Communications.
[29] E. Fish,et al. The yin and yang of viruses and interferons , 2012, Trends in Immunology.
[30] R. Brookmeyer,et al. Incubation periods of acute respiratory viral infections: a systematic review , 2009, The Lancet Infectious Diseases.
[31] J. Taubenberger,et al. The pathology of influenza virus infections. , 2008, Annual review of pathology.
[32] R. Baric,et al. Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain , 2007, Journal of Virology.
[33] P. Palese,et al. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists , 2006, Journal of Virology.
[34] W. Lim,et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.
[35] G. Sen,et al. Viruses and interferons. , 2001, Annual review of microbiology.